The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- Does This Marijuana Drug Study Change Everything?
- Why Dyax Corp. Stock Exploded Higher Today
- Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
- Why BioMarin Pharmaceutical Inc. Stock Is Surging Today
- Why Amicus Therapeutics, Inc. Stock Is Soaring Today
- Why Retrophin, Inc. Stock Surged Today